TORONTO, April 23, 2018 -- Axiom Real-Time Metrics, premier provider of unified eClinical solutions and services, is exhibiting at Clinical Operations in Oncology Trials West on April 24th and 25th in Burlingame, California.
The 2018 event is the 5th annual edition of the conference and brings together leading pharma and biotech professionals working in the oncology space from across the West Coast region.
“Fusion eClinical Suite provides uniquely tailored reports to support clinical oncology studies, including tumour response assessment and tracking, patient profiles, and biomarker reports. Axiom’s client roster includes many sponsors working on global oncology and plasma cell disorders including studies for the treatment of Multiple Myeloma, AML, CML, Hodgkin Lymphoma and Leukemia, among others. The easy-to-use, modular suite of tools is extremely flexible, enabling sponsors to manage all study data from Phase I to complex Phase III trials without having to change platforms or source additional vendors. It works exceptionally well for all studies, supporting US to global studies and enabling them to operate with far greater efficiency - speeding time to market,” shared Dr. Robert Arbeit, Chief Clinical Scientist.
Andrew Schachter, Founder and CEO concluded, “Our established ROI and delivery positions us as both cost efficient and best-in-class. We invite attendees to come and visit us at Booth 4 for a conversation and tailored demo over coffee.”
About Axiom Real-Time Metrics
Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: DM, Biostatistics and Pharmacovigilance. Axiom's eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.
Contact
[email protected]
+1.877.321.9191
PR Contact
Sarah Glofcheskie
[email protected]
+1.647.588.9073


Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
How Marco Pharma International Preserves German Homeopathic Traditions in America
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 



